Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 4 3Phase 2 2Phase 1/2 2Phase EARLY_PHASE1 1

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Recurrence 1Neoplasms 1Cytokine Release Syndrome 1Cancer Therapy-related Cardiovascular Toxicity 1Arthritis, Rheumatoid 1

Interventions

Dexamethasone 11Lenalidomide 10Bortezomib 9Zoledronic Acid 8ixazomib 4daratumumab 4Melphalan 4tocilizumab 3Thalidomide 3Cyclophosphamide 3pomalidomide 2carfilzomib 2Prednisone 2Kyphoplasty 2Filgrastim 2Doxorubicin 2Calcium Dobesilate 2zanubrutinib 1talquetamab 1pegylated granulocyte colony-stimulating factor 1montelukast 1isatuximab 1ibrutinib 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1apixaban 1Vaccination 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Multiple Myeloma × tocilizumab × Clear all
NCT07609940 2026-05-27

POPLIN

Regeneron Pharmaceuticals

Phase 4 Not yet recruiting
30 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

NCT06251076 2025-12-10

Plan Development for Giving Teclistamab in the Outpatient Setting

University Health Network, Toronto

Phase 4 Recruiting
15 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT05855122 2023-06-02

Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients

The First Affiliated Hospital of Soochow University

Phase 4 Unknown
48 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡